Stock Financial Ratios, Dividends, Split History

ADP / Automatic Data Processing, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)50,351.08
Enterprise Value ($M)50,580.08
Book Value ($M)4,029.20
Book Value / Share9.15
Price / Book12.81
NCAV ($M)-1,322.30
NCAV / Share-3.00
Price / NCAV-46.17
Share Statistics
Common Shares Outstanding 444,374,752
Weighted Average Number Of Shares Outstanding Basic 447,800,000
Common Stock Shares Outstanding 445,000,000
Effect Of Employee Restricted Stock Shares On Weighted Average Number Of Diluted Shares Outstanding 1,600,000
Weighted Average Number Of Diluted Shares Outstanding 450,300,000
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.29
Return on Assets (ROA)0.04
Return on Equity (ROE)0.39
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio1.05
Income Statement (mra) ($M)
PEO Revenues3,464,300,000.00
Sales Revenue Net8,518,100,000.00
Net Income1,733.40
Earnings Per Share Basic3.87
Earnings Per Share Diluted3.85
Cash Flow Statement (mra) ($M)
Cash From Operations2,125.90
Cash from Investing5,730.40
Cash from Financing5,730.40
Identifiers and Descriptors
Central Index Key (CIK)8670
Related CUSIPS
053015953 053015903 530151034

Split History

Stock splits are used by Automatic Data Processing, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related News Stories

Pershing Square analyst Brian Welch to leave company

15h reuters
(Reuters) - Willliam Ackman’s hedge fund Pershing Square Capital Management LP said on Tuesday that Brian Welch, who led research efforts on Automatic Data Processing Inc (ADP.O), one of the firm’s recent investments, was leaving the company. (44-0)

Pershing Square Sends Communication to Investors Regarding ADP | Business Wire

16h businesswire
Pershing Square Holdings, Ltd. (LN: PSH) (NA: PSH) today released an email sent from Pershing Square Capital Management, L.P. to its investors. The text of the email is set forth below: (45-0)

Philip Morris International: Great High Dividend Income Yield Of 5.6% While Waiting For Mr. Market To Get Smart

2018-06-18 seekingalpha
Philip Morris has increased its dividend for 10 of the last ten years in a row and presently has a yield of 5.6%, which is well above average. (140-0)

20 Nasdaq-100 Stocks That Will Heat Up 2H18

2018-06-15 investorplace
Unless you’ve been living under a rock, you know that the narrative surrounding broad markets — it’s been one of strife since late January until the recent rally. Volatility spiked and the S&P 500 Index still sits almost 3% below late-January highs. (2079-8)

Sherwin-Williams: Buy For Great Total Return And Steady Dividend

2018-06-13 seekingalpha
Sherwin-Williams' total return over-performed the Dow average for my 53.0-month test period by 73.11%, which is great. (118-0)

CUSIP: 053015103